OLEMA PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$34.11 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-16
- OLEMA PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$34.11M.
- OLEMA PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$27.31M.
- OLEMA PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$20.06M.
- OLEMA PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$21.93M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$34.11M 10-K · filed 2026-03-16 | |
| 2024-12-31 | -$27.31M 10-K · filed 2026-03-16 | |
| 2023-12-31 | -$20.06M 10-K · filed 2025-03-18 | |
| 2022-12-31 | -$21.93M 10-K · filed 2024-03-11 | |
| 2021-12-31 | -$14.93M 10-K · filed 2023-03-09 | $14.93M 10-K · filed 2022-02-28 |
| 2020-12-31 | $4.76M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |